Key Points
- COO Kathleen Goin sold 4,302 shares on Jan. 21 at an average of $97.63 for $420,004.26 and completed identical sales on Dec. 17 and Nov. 19, totaling roughly $1.21 million in insider sales over those three transactions.
- Shares are trading down ~7.4% to $85.30 after reporting a quarterly EPS miss (‑$1.03 vs. ‑$0.85), yet Wall Street remains bullish—analysts average a $158.69 price target with mostly Buy/Strong Buy ratings.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the firm's stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, December 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $96.47, for a total value of $415,013.94.
- On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46.
Palvella Therapeutics Trading Down 7.4%
Shares of NASDAQ PVLA opened at $85.30 on Friday. Palvella Therapeutics, Inc. has a 1 year low of $12.10 and a 1 year high of $114.69. The firm's 50-day moving average is $97.37 and its 200-day moving average is $70.38. The firm has a market capitalization of $1.01 billion, a PE ratio of -32.43 and a beta of -0.16.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.18). As a group, equities research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on PVLA. BTIG Research reissued a "buy" rating and issued a $192.00 price target on shares of Palvella Therapeutics in a research note on Friday, January 16th. UBS Group reissued a "buy" rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Chardan Capital boosted their target price on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. Truist Financial upped their price target on Palvella Therapeutics from $105.00 to $190.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $158.69.
Get Our Latest Research Report on Palvella Therapeutics
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics during the third quarter worth about $28,000. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics during the 3rd quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $37,000. JPMorgan Chase & Co. raised its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics in the second quarter valued at approximately $85,000. 40.11% of the stock is owned by institutional investors and hedge funds.
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
